Key Points
- Insider Mike Mensinger sold 2,650 Beta Bionics shares at $22 each for $58,300, reducing his position by 1.49% to 174,740 shares. He also made two earlier sales totaling 7,025 shares.
- Beta Bionics reported a quarterly loss of $0.52 per share, slightly better than the $0.53 consensus estimate, while revenue reached $35.51 million. The company remains unprofitable, with a negative net margin of 65.31%.
- Analyst sentiment remains broadly favorable, with a consensus “Moderate Buy” rating and an average price target of $23.69, but the company faces legal and execution risks related to alleged iLet safety disclosures and the launch of its next-generation Mint pump.
Beta Bionics, Inc. (NASDAQ:BBNX - Get Free Report) insider Mike Mensinger sold 2,650 shares of the stock in a transaction dated Tuesday, October 27th. The stock was sold at an average price of $22.00, for a total transaction of $58,300.00. Following the completion of the transaction, the insider directly owned 174,740 shares of the company's stock, valued at $3,844,280. This trade represents a 1.49% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
Mike Mensinger also recently made the following trade(s):
- On Wednesday, September 16th, Mike Mensinger sold 2,650 shares of Beta Bionics stock. The shares were sold at an average price of $22.00, for a total transaction of $58,300.00.
- On Wednesday, September 2nd, Mike Mensinger sold 4,375 shares of Beta Bionics stock. The stock was sold at an average price of $19.11, for a total transaction of $83,606.25.
Beta Bionics Trading Down 1.5%
Beta Bionics stock opened at $17.58 on Friday. The stock has a 50-day moving average price of $19.16 and a two-hundred day moving average price of $14.89. Beta Bionics, Inc. has a 12 month low of $8.80 and a 12 month high of $32.71.
Beta Bionics (NASDAQ:BBNX - Get Free Report) last posted its earnings results on Tuesday, October 27th. The company reported ($0.52) EPS for the quarter, topping the consensus estimate of ($0.53) by $0.01. The business had revenue of $35.51 million for the quarter. Beta Bionics had a negative net margin of 65.31% and a negative return on equity of 27.33%. As a group, equities analysts predict that Beta Bionics, Inc. will post -2.02 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Squarepoint Ops LLC bought a new position in shares of Beta Bionics during the 2nd quarter worth $2,524,000. Bank of America Corp DE bought a new position in Beta Bionics during the second quarter worth about $8,566,000. Man Group plc purchased a new position in shares of Beta Bionics in the second quarter worth about $419,000. Legal & General Group Plc bought a new stake in shares of Beta Bionics in the second quarter valued at approximately $62,000. Finally, The Manufacturers Life Insurance Company bought a new stake in shares of Beta Bionics in the second quarter valued at approximately $172,000.
More Beta Bionics News
Here are the key news stories impacting Beta Bionics this week:
- Positive Sentiment: Third-quarter results slightly exceeded expectations. Beta Bionics reported a loss of $0.52 per share versus the consensus estimate of a $0.53 loss, while revenue of $35.51 million topped analyst expectations of roughly $34.7 million. The company also updated its 2026 guidance, though details were not provided in the available reports. Beta Bionics third-quarter results
- Positive Sentiment: Analyst support remains favorable. Stifel Nicolaus maintained its Buy rating, while other analysts have raised price targets. The consensus rating remains Moderate Buy, with an average target price of $23.69, above the recent trading level.
- Neutral Sentiment: Insider selling was relatively limited in the latest filings. Director Mark Hopman sold 821 shares for approximately $16,420, reducing his ownership by about 1.48%. Another insider, Mike Mensinger, sold 2,650 shares for $58,300. The transactions may weigh on sentiment, but represent small portions of their remaining holdings. SEC insider filing
- Negative Sentiment: Multiple law firms publicized a pending securities class action. The lawsuit covers investors who purchased BBNX shares between July 30, 2025, and February 24, 2026. Investors have until November 3, 2026, to seek lead-plaintiff status. The repeated notices increase legal and reputational risks for Beta Bionics.
- Negative Sentiment: The allegations focus on FDA and iLet safety disclosures. Legal notices allege that the company’s filings did not fully disclose issues tied to an FDA warning and hundreds of potentially serious iLet complaints, including alleged life-threatening hypoglycemia incidents. These claims have not been proven, but possible regulatory action, litigation costs, or additional product concerns could pressure the stock. Beta Bionics securities class action notice
- Negative Sentiment: Execution risk remains an additional concern. The company has disclosed risks related to the commercial launch of its next-generation Mint patch pump, potentially clouding its growth outlook.
Analyst Ratings Changes
Several research firms have recently commented on BBNX. William Blair initiated coverage on shares of Beta Bionics in a research report on Friday, August 21st. They set a "market perform" rating for the company. TD Cowen increased their target price on shares of Beta Bionics from $18.00 to $21.00 and gave the company a "hold" rating in a report on Wednesday. Robert W. Baird raised their price target on shares of Beta Bionics from $14.00 to $16.00 and gave the company a "neutral" rating in a research report on Tuesday, September 15th. Wall Street Zen raised shares of Beta Bionics from a "sell" rating to a "hold" rating in a research report on Saturday, September 19th. Finally, Weiss Ratings upgraded Beta Bionics from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Tuesday, August 18th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $23.69.
Read Our Latest Stock Analysis on Beta Bionics
Beta Bionics Company Profile
(
Get Free Report)
Beta Bionics, Inc (NASDAQ: BBNX) is a medical technology company focused on developing and commercializing automated insulin-delivery systems for people with insulin-dependent diabetes. Its principal product is the iLet Bionic Pancreas, an automated insulin-delivery system designed to help manage blood glucose levels with limited user input.
The iLet Bionic Pancreas combines a wearable insulin pump with continuous glucose monitoring technology and adaptive dosing algorithms. The system is designed to automatically adjust insulin delivery based on an individual's glucose readings and requires users to provide relatively simple meal announcements rather than calculate precise carbohydrate amounts.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
